

# Night Vision Disturbances Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/NA9CA8C14DFCEN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: NA9CA8C14DFCEN

## Abstracts

The 7 major night vision disturbances markets reached a value of US\$ 308.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 430.5 Million by 2034, exhibiting a growth rate (CAGR) of 3.07% during 2024-2034.

The night vision disturbances market has been comprehensively analyzed in IMARC's new report titled "Night Vision Disturbances Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Night vision disturbances refer to the impaired ability to see clearly in low-light conditions, often experienced as an unsettling disruption in one's visual perception during nighttime or dimly lit environments. Individuals suffering from the ailment may encounter a range of symptoms, such as difficulty discerning objects, increased sensitivity to glare, halos, or starbursts around lights, and decreased contrast sensitivity. These indications can affect the quality of life, particularly when engaging in activities that require adequate night vision, including driving or navigating in the dark. The diagnosis of the illness typically involves a comprehensive eye investigation by an ophthalmologist or optometrist. The healthcare professional will assess factors, such as refractive errors, pupil size, and the overall health of the eye's structures. In some cases, various specialized tests, like contrast sensitivity testing and measurements of the eye's aberrations, may be conducted to pinpoint the exact nature of the visual disturbance in patients.

The increasing cases of retinal abnormalities causing degeneration of the cells, particularly the rods responsible for dim light vision, are primarily driving the night vision disturbances market. In addition to this, the inflating utilization of innovative corrective methods, such as specialized glasses, contact lenses, and vitamin supplements, to enhance and protect night vision in individuals suffering from the disorder is also

creating a positive outlook for the market. Moreover, the widespread adoption of advanced imaging procedures, including adaptive optics and retinal scans, which enable precise diagnosis and personalized treatment plans, thereby improving the quality of life, is further bolstering the market growth. Apart from this, the rising usage of cutting-edge interventions, like retinal implants and neurostimulation techniques, since they are aimed at mitigating the condition and restoring optimal nocturnal visual capabilities in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of tailored vision therapies that are designed to enhance retinal sensitivity, refine neural adaptation, and ameliorate low-light vision is also propelling the market growth. Furthermore, the escalating application of gene-based interventions, encompassing gene augmentation and gene editing strategies, to help in rectifying the genetic anomalies responsible for the disorder is expected to drive the night vision disturbances market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the night vision disturbances market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for night vision disturbances and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the night vision disturbances market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the night vision disturbances market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the night vision disturbances market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current night vision disturbances marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:  
Market Insights

How has the night vision disturbances market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the night vision disturbances market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the night vision disturbances market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of night vision disturbances across the seven major markets?

What is the number of prevalent cases (2018-2034) of night vision disturbances by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of night vision disturbances by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with night vision disturbances across the seven major markets?

What is the size of the night vision disturbances patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of night vision disturbances?

What will be the growth rate of patients across the seven major markets?

### Night Vision Disturbances: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for night vision disturbances drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the night vision disturbances market?

What are the key regulatory events related to the night vision disturbances market?

What is the structure of clinical trial landscape by status related to the night vision disturbances market?

What is the structure of clinical trial landscape by phase related to the night vision disturbances market?

What is the structure of clinical trial landscape by route of administration related to the night vision disturbances market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 NIGHT VISION DISTURBANCES - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 NIGHT VISION DISTURBANCES - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 NIGHT VISION DISTURBANCES - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 NIGHT VISION DISTURBANCES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 NIGHT VISION DISTURBANCES - UNMET NEEDS**

## **10 NIGHT VISION DISTURBANCES - KEY ENDPOINTS OF TREATMENT**

## **11 NIGHT VISION DISTURBANCES - MARKETED PRODUCTS**

- 11.1 List of Night Vision Disturbances Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 NIGHT VISION DISTURBANCES - PIPELINE DRUGS**

### 12.1 List of Night Vision Disturbances Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Phentolamine mesylate ophthalmic solution - Ocuphire Pharma

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. NIGHT VISION DISTURBANCES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. NIGHT VISION DISTURBANCES – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 NIGHT VISION DISTURBANCES - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Night Vision Disturbances - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Night Vision Disturbances - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Night Vision Disturbances - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Night Vision Disturbances - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

- 15.3.3 Night Vision Disturbances - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Night Vision Disturbances - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Night Vision Disturbances - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Night Vision Disturbances - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Night Vision Disturbances - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Night Vision Disturbances - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Night Vision Disturbances - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Night Vision Disturbances - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Night Vision Disturbances - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Night Vision Disturbances - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Night Vision Disturbances - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Night Vision Disturbances - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Night Vision Disturbances - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Night Vision Disturbances - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Night Vision Disturbances - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)

- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Night Vision Disturbances - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Night Vision Disturbances - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Night Vision Disturbances - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Night Vision Disturbances - Access and Reimbursement Overview

## **16 NIGHT VISION DISTURBANCES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 NIGHT VISION DISTURBANCES MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 NIGHT VISION DISTURBANCES MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Night Vision Disturbances Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/NA9CA8C14DFCEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NA9CA8C14DFCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

